GRI Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference
GRI(NASDAQ:GRI) Live webcast presentation with CEO, Dr. Marc Hertz, on September 9th at 3:00 PM ET
September 3, 2025Investor Event
Read more →GRI Bio to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
GRILive video webcast on Wednesday, August 20th at 2:20 PM ET
August 14, 2025Webinar
Read more →HC Wainwright & Co. Reiterates Buy on GRI Bio, Maintains $10 Price Target
GRIJune 11, 2025
Read more →Ascendiant Capital Maintains Buy on GRI Bio, Lowers Price Target to $34
GRIMay 27, 2025
Read more →GRI Bio Presents Preclinical Data Demonstrating Lead Program GRI-0621 Has Anti-Inflammatory And Anti-Fibrotic Effects In Pulmonary Fibrosis At 2025 ATS International Conference
GRIMay 22, 2025
Read more →GRI Bio Q1 EPS $(5.80) Misses $(4.11) Estimate
GRIMay 15, 2025
Read more →GRI Bio Reports Interim Biomarker Results From Phase 2a Study Evaluating GRI-0621 In Idiopathic Pulmonary Fibrosis; Independent Data Monitoring Committee Recommended Study Continue As Planned, As No Safety Concerns Were Seen In The Data Reviewed
GRIMay 8, 2025
Read more →GRI Bio Completes Enrollment With 24 Of 36 Planned Patients Randomized In Its Ongoing Phase2a Study Evaluating GRI-0621 For Idiopathic Pulmonary Fibrosis
GRIMay 7, 2025
Read more →HC Wainwright & Co. Reiterates Buy on GRI Bio, Maintains $10 Price Target
GRIApril 14, 2025
Read more →GRI Bio Prices $5.0M Public Offering Of 1,388,888 At $3.60
GRIApril 1, 2025
Read more →Why Is Nano Cap GRI Bio Stock Skyrocketing On Tuesday?
GRIGRI Bio reported interim Phase 2a results for GRI-0621 in IPF, showing safety and no significant cholesterol changes.
April 1, 2025
Read more →GRI Bio Shares Resumed Trade And Then Again Halted On Circuit Breaker To The Downside, Stock Now Up 154.1%
GRIApril 1, 2025
Read more →GRI Bio Reported Interim 2-Week Safety Results From Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis
GRIApril 1, 2025
Read more →GRI Bio Expands Intellectual Property Portfolio With Granting of Two Global Patents in Europe and Japan
GRIMarch 31, 2025
Read more →GRI Bio Reports As Of December 31, 2024, The Company Had Cash And Cash Equivalents Of ~$5M; Cash Runway Expected To Fund Operations Into Q2 2025, Including Interim Data Readout From GRI-0621
GRIMarch 17, 2025
Read more →GRI Bio Regains Compliance With Nasdaq's Minimum Bid Price Rule
GRIMarch 11, 2025
Read more →Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending
GRIFebruary 22, 2025
Read more →GRI Bio Announces 1-For-17 Reverse Stock Split, Expected To Begin Trading On A Post-Split Adjusted Basis On February 24, 2025
GRIFebruary 19, 2025
Read more →GRI Bio Secures European Patent Approval For GRI-0803 And 500+ Proprietary Compounds
GRIDecember 23, 2024
Read more →GRI Bio Q3 EPS $(0.67) Up From $(65.78) YoY
GRINovember 14, 2024
Read more →GRI Bio Files For Offer And Resale By Selling Stockholders Of Up To 1,577,829 Shares Of Common Stock
GRINovember 14, 2024
Read more →GRI Bio Presents Preclinical Data From Pipeline Of NKT Cell Modulators In Development For Systemic Lupus Erythematosus
GRIMay 21, 2024
Read more →GRI Bio Presents Preclinical Data Demonstrating GRI-0621 Reduces The Important Inflammatory And Fibrotic Drivers In Idiopathic Pulmonary Fibrosis
GRIMay 20, 2024
Read more →